SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to surging interest in nuclear energy's potential to power AI data centers, with the stock experiencing a significant climb. Community members are actively debating whether the current valuation is justified given the company's pre-revenue status, with some pointing to potential overvaluation and others anticipating further upside based on future projects.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as traders discuss a potential short squeeze and draw comparisons to other AI defense stocks like Palantir. The community is focused on key resistance levels, anticipating a continued rally and eyeing a move towards higher price targets. Some traders speculate on upcoming news or contract announcements as potential catalysts for further growth.

AGM Group Holdings, Inc. is a technology company, which engages in the provision of financial solutions. It focuses on the research and development of blockchain-oriented ASIC chip, production of encryption mining machines, and financial technology software services. Its products and services include technology hardware research and development, and assembling and sales of technology hardware. The company was founded by Zhen Tao Jiang and Wen Jie Tang on April 27, 2015 and is headquartered in Hong Kong.

AGM Group Holdings Inc - Ordinary Shares - Class A

AGMH is experiencing a surge, driven by a restatement regarding the sale of its Nanjing Lucun subsidiary. The community is actively discussing the stock's potential for a short squeeze given its low float and high short interest, while some express concerns about potential overextension.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is surging amid renewed interest in quantum computing, fueled by news of a recent Air Force contract and progress in DARPA's Quantum Benchmarking Initiative. The community is actively discussing potential upside targets and whether the stock is overvalued, while some traders are taking profits after recent gains. Interest in related sectors such as materials suppliers and quantum-resistant crypto are also part of the conversation.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as the community discusses its potential to catch up to competitor Joby in terms of price action, with many citing upcoming catalysts like the Abu Dhabi Air Show and government contracts. Optimism is fueled by the belief that Archer is undervalued and poised for a short squeeze, with the $10-$11 range being a key resistance level to watch.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending due to growing momentum in the quantum computing sector, fueled by strong bookings growth in the APAC region, new partnerships, and a breakout to fresh 52-week highs. Community members are discussing the potential for a continued rally, comparing QBTS to other quantum players like IONQ and RGTI, and speculating on potential acquisition targets. Some traders are also noting the high short interest, suggesting a possible short squeeze.

Veritone, Inc. engages in the provision of artificial intelligence (AI) computing solutions to media and entertainment, government, and legal and compliance industries. It operates through the following segments: Advertising, aiWARE SaaS Solutions, and aiWARE Content Licensing and Media Services. The Advertising segment places advertisements for clients, primarily with radio broadcasters, podcasters and digital media producers. The aiWARE SaaS Solutions segment offers solutions through a combination of its direct sales force and indirect channel partners, such as value-added resellers (VARs), distributors, system integrators, managed services providers, and referral partners. The aiWARE Content Licensing and Media Services segment sells and markets activities relating to its digital content licensing services business through its direct sales force. The company was founded by Chad Edward Steelberg and Ryan S. Steelberg on June 13, 2014 and is headquartered in Denver, CO.

Veritone Inc

VERI is trending due to a recent analyst price target increase to $26, citing the company's potential in the AI data refinery market, which has sparked significant community discussion around its valuation relative to peers like PLTR. The community highlights Veritone's AI computing solutions and services, particularly its aiWARE platform, with some viewing it as undervalued in the current AI landscape. High trading volume and mentions of potential partnerships have further fueled interest in the stock.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending amid community discussions on potential connections to Psi Quantum and speculation about future price movement, while some traders point to technical indicators suggesting both upward potential and valuation concerns. The stock's momentum is debated, with some highlighting its breakout potential within the quantum computing sector, while others express skepticism about its commercial viability and potential for a pullback. Overall, the community's focus remains on QUBT's position within the broader quantum computing landscape and its potential for further gains.

KULR Technology Group, Inc. engages in developing, manufacturing, and licensing next-generation carbon fiber thermal management technologies for batteries and electronic systems. Its products include cellcheck, safecase, thermal capacitor, fiber thermal interface, thermal runaway shield, internal short circuit, and cathode. The company was founded by Michael Mo and Timothy R. Knowles in December 2015 and is headquartered in Webster, TX.

KULR Technology Group Inc

KULR is trending due to discussions around its potential in the drone battery market and recent partnerships, with community members highlighting its NASA-proven technology. Bullish sentiment is fueled by expectations of increased revenue from new contracts, particularly in the defense sector, while others express concern over dilution and the company's Bitcoin strategy. Technical analysis suggests a potential uptrend if key resistance levels are broken.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending as investors discuss upcoming catalysts like satellite launches, commercial agreements, and potential regulatory approvals, while also highlighting the company's strategic partnerships. Community members express confidence in the stock's long-term potential, viewing current price levels as an opportunity ahead of anticipated milestones. Discussions also reference the broader context of satellite-based cellular connectivity and its potential impact on the telecom industry.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IMUNON, Inc. (IMNN) said on Wednesday its first patient has been dosed with the firm’s lead candidate, IMNN-001, as part of a late-stage trial evaluating the drug in the treatment of women with newly diagnosed advanced ovarian cancer.Shares of the company traded 4% higher in morning trade at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMNN">IMUNON</a> jumped from ‘bearish’ to ‘neutral’ over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_9_43_26_AM_png_dc891d230b.webp" alt="IMNN's Sentiment Meter and Message Volume as of 10 a.m. ET on July 30, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>IMNN's Sentiment Meter and Message Volume as of 10 a.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company is undervalued.<stembedurl>https://stocktwits.com/ConcernedCitizen23/message/623007565</stembedurl>The late-stage <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.imunon.com/news-releases/news-release-details/imunon-announces-first-patient-dosed-phase-3-ovation-3-study">study</a> is aimed at assessing the safety and efficacy of IMNN-001 plus standard of care neoadjuvant and adjuvant chemotherapy of Paclitaxel and Carboplatin compared to standard of care chemotherapy alone.The primary endpoint of the study is overall survival or lengthening the lifespan of patients.The study will also check secondary endpoints such as surgical response score, chemotherapy response score, clinical response, and time to second-line treatment.“We have great urgency around this program because patients do not have any other options besides the standard of care, which includes neoadjuvant and adjuvant chemotherapy and surgery,” CEO Stacy Lindborg said.According to IMUNON, epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year, and approximately 70% are diagnosed in advanced Stage III/IV, the company said.Earlier this month, IMUNON completed a reverse stock split of its issued and outstanding common stock at a ratio of 1:15 to meet the minimum bid price requirement for continued listing on the Nasdaq.IMNN stock is down by 43% this year and by about 84% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/humana-announces-upbeat-earnings-raised-guidance/choXGmPR5zr">Humana Stock Gains On Upbeat Earnings And Raised Guidance, Draws Retail Praise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued

The trial is evaluating IMNN-001 in the treatment of women with newly diagnosed advanced ovarian cancer. 

Equity

The trial is evaluating IMNN-001 in the treatment of women with newly diagnosed advanced ovarian cancer. 


Imunon hit its highest levels in nearly three years Tuesday, fueled by its announcement to present Phase 2 OVATION 2 study immune biomarker data at the European Society for Medical Oncology Gynaecological Cancers Congress 2025.The accepted abstract presents the results of IMNN-001, an IL-12 gene therapy developed from Imunon's TheraPlas platform, used in conjunction with neoadjuvant and adjuvant chemotherapy treatments for newly diagnosed, advanced ovarian cancer patients.Imunon shares surged 95.69% to close at $2.27 on May 27, before pulling back 23.35% in after-hours trading to $1.74.Premal H. Thaker, the chair of the Ovation 2 and 3 study, will deliver the presentation at the June 19–21 Vienna-based congress.The announcement follows recent news that new Ovation 2 data will also be featured in an oral presentation at the 2025 ASCO Annual Meeting and published in Gynecologic Oncology.&nbsp;These results showed meaningful increases in overall and progression-free survival for the IMNN-001 treatment group, with a median 13-month improvement in overall survival.CEO Stacy Lindborg called the data “remarkable” and said the growing interest from EU and Latin American researchers reinforces confidence in the company’s Phase 3 Ovation 3 trial and regulatory ambitions.&nbsp;The Phase 3 Ovation 3 trial, which recently initiated its first two sites, will evaluate IMNN-001 plus chemotherapy versus chemotherapy alone in patients with Stage IIIC or IV epithelial ovarian cancer.&nbsp;The primary endpoint is overall survival.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,554% surge in 24-hour message volume.One user commented that anyone worried about the after-hours drop should note that the stock behaved similarly last Friday, followed by a strong run the next day.&nbsp;<stembedurl>https://stocktwits.com/NFD2/message/615992363</stembedurl>Another user highlighted the possibility of an upcoming press release announcing a major partnership with a big pharmaceutical company to support funding and potential licensing or commercialization deals, citing CEO comments from recent weeks.<stembedurl>https://stocktwits.com/gourmetmacncheese/message/615991264</stembedurl>The stock has risen 116% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon

The data highlights promising results for IMNN-001, an IL-12 gene therapy for advanced ovarian cancer, boosting investor optimism ahead of its Phase 3 trial.

Retail buzz around Imunon rose sharply Thursday after the clinical-stage biotech company said it will no longer pursue a previously planned public offering.&nbsp;Imunon formally requested to retract its Form S-1 registration with the SEC after initially registering the document on April 4.The biotech firm's shares rose 4.1% to $0.42 on Thursday and surged another 15.5% in after-hours trading to $0.48.The news follows a first-quarter (Q1) financial update, which showed that Imunon decreased its net loss from $4.9 million last year to $4.1 million.Imunon reported a per-share loss of $0.28, below the consensus estimate of $0.36.R&amp;D cost reductions totaling $1.1 million drove an 18% decrease in operating expenses, bringing the total to $4.1 million.&nbsp;The decline was driven by spending reductions on the Ovation 2 study, the PlaCCine DNA vaccine trial, and platform development activities.Employee-related costs&nbsp;increased, causing general and administrative expenses to rise slowly to $2.0 million from $1.7 million last year, although lower legal fees helped partially offset this increase.The operating activities required $2.8 million in cash, a reduction of more than half compared to the $5.9 million used in Q1 2024.As of quarter-end, Imunon maintained $2.9 million in cash reserves and projects that these funds will support operations until late Q2 2025.CEO Stacy Lindborg highlighted clinical advancements, including the Ovation 3 pivotal study and ongoing results from the Ovation 2 trial, which showed that the DNA-based immunotherapy IMNN-001 increased progression-free and overall survival rates among patients newly diagnosed with ovarian cancer.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,120% surge in 24-hour message volume.One user suggested the move implies management may have “a much better option for funding,” citing recent earnings call comments from the CEO about active financing and partnership discussions.&nbsp;<stembedurl>https://stocktwits.com/ItTakesItAll/message/615624018</stembedurl>Another user called the update “great news,” pointing to the company’s low float.<stembedurl>https://stocktwits.com/ItTakesItAll/message/615621205</stembedurl>The stock has declined 60.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of scientist hand inoculating an agar plates with bacteria in microbiology lab | Image source: Getty Images

Retail Bulls Cheer Imunon’s Pullback From Public Offering, Citing ‘Much Better Funding Options’

Shares jumped 15.5% after hours, as retail traders pointed to “much better funding options” hinted at during the firm’s recent earnings call.

Earnings Outlook For Imunon

Equities Analysts Issue Forecasts for Imunon, Inc.'s Q1 2024 Earnings (NASDAQ:IMNN)

Imunon, Inc. (NASDAQ:IMNN - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings estimates for Imunon in a research report issued to clients and investors on Monday...

Imunon, Inc. (NASDAQ:IMNN) Short Interest Down 8.6% in March

Imunon, Inc. (NASDAQ:IMNN - Get Free Report) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 449,100 shares, a drop of 8.6% from...

Imunon price target raised by $1 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Q4 2023 Imunon Inc Earnings Call Transcript

Imunon sees cash runway into 4Q24

Imunon reports 2023 EPS ($2.16) vs. ($5.03) last year

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Imunon Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$4.99
Prev Close	$5.10
Open	$5.16
Dividend Yield	0.00%
50-Day Moving Average	$6.54
Beta	0.56
Avg. Volume	82,985.13
PE Ratio	-0.38

52-Week High	$41.22
52-Week Low	$4.83
Market Capitalization	$12.86M
EPS (Annual)	-$21.10
Price to Book	3.79
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IMNN
Imunon Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IMNN News

IMNN Imunon Inc